On a conference call last week, Keryx executives said Zerenex's patent estate is strong but issue of the drug's NCE status was not brought up. Like Amarin, Keryx is expected to seek either a partner to help sell Zerenex once approved or seek a buyer for the company outright.
JMP Securities analyst Jason Butler came to Keryx's defense Monday. "While we acknowledge that this issue
On Friday, an institutional investor long Keryx shares called the IPD report "bogus" and said his due diligence checks left him confident that Zerenex was eligible for NCE status.
Interestingly, another investor, more bearish on Keryx and skeptical about Zerenex's commercial potential, agreed, saying the NCE concern was overblown.
$KERX: I spoke w/ bull & bearabout Zerenex NCE "controversy" -- both thought issue was overblown, not likely to be a problem.— Adam Feuerstein (@adamfeuerstein) February 1, 2013-- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts